Celcuity Inc (NASDAQ:CELC) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 37,700 shares, a decrease of 64.6% from the June 30th total of 106,400 shares. Based on an average daily trading volume, of 32,200 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the company’s stock are short sold.
Shares of CELC stock opened at $5.30 on Friday. Celcuity has a 12-month low of $4.03 and a 12-month high of $23.80. The firm’s 50 day moving average is $6.64 and its 200 day moving average is $7.78. The stock has a market capitalization of $54.45 million, a P/E ratio of -6.97 and a beta of 0.97.
Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.02). On average, analysts predict that Celcuity will post -0.81 EPS for the current year.
Several hedge funds have recently made changes to their positions in the company. State Street Corp raised its position in shares of Celcuity by 4.3% during the 1st quarter. State Street Corp now owns 89,657 shares of the company’s stock valued at $583,000 after purchasing an additional 3,683 shares during the period. Wells Fargo & Company MN increased its holdings in Celcuity by 44.8% in the 1st quarter. Wells Fargo & Company MN now owns 15,001 shares of the company’s stock valued at $97,000 after acquiring an additional 4,641 shares during the last quarter. Gagnon Securities LLC increased its holdings in Celcuity by 14.9% in the 1st quarter. Gagnon Securities LLC now owns 196,877 shares of the company’s stock valued at $1,280,000 after acquiring an additional 25,545 shares during the last quarter. Frontier Wealth Management LLC increased its holdings in Celcuity by 1.5% in the 1st quarter. Frontier Wealth Management LLC now owns 732,606 shares of the company’s stock valued at $4,762,000 after acquiring an additional 10,501 shares during the last quarter. Finally, UBS Group AG increased its holdings in Celcuity by 196.2% in the 1st quarter. UBS Group AG now owns 22,955 shares of the company’s stock valued at $149,000 after acquiring an additional 15,204 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.
A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Celcuity in a report on Tuesday, July 14th. Craig Hallum assumed coverage on shares of Celcuity in a report on Monday, May 11th. They set a “buy” rating on the stock. Finally, Zacks Investment Research upgraded shares of Celcuity from a “sell” rating to a “hold” rating in a report on Wednesday, July 8th.
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Read More: What are the FAANG Stocks?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.